Total Payments
$449,910
2024 Payments
$26,869
Companies
18
Transactions
505
Medicare Patients
376
Medicare Billing
$64,945
Payment Breakdown by Category
Consulting$328,289 (73.0%)
Travel$87,480 (19.4%)
Research$25,677 (5.7%)
Food & Beverage$8,458 (1.9%)
Education$5.56 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $328,289 | 87 | 73.0% |
| Travel and Lodging | $87,480 | 134 | 19.4% |
| Unspecified | $25,677 | 16 | 5.7% |
| Food and Beverage | $8,458 | 267 | 1.9% |
| Education | $5.56 | 1 | 0.0% |
Payments by Type
General
$424,233
489 transactions
Research
$25,677
16 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| EMD Serono, Inc. | $79,441 | 49 | $0 (2020) |
| Eli Lilly and Company | $74,952 | 194 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $65,883 | 58 | $0 (2024) |
| ABBVIE INC. | $46,706 | 56 | $0 (2024) |
| EMD Serono Research & Development Institute | $38,484 | 22 | $0 (2017) |
| Celgene Corporation | $27,833 | 16 | $0 (2019) |
| AstraZeneca UK Limited | $22,192 | 18 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $18,383 | 14 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $17,122 | 21 | $0 (2019) |
| BioNTech SE | $16,258 | 11 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $26,869 | 22 | BioNTech SE ($16,213) |
| 2023 | $44.84 | 1 | BioNTech SE ($44.84) |
| 2021 | $198.96 | 1 | Eli Lilly and Company ($198.96) |
| 2020 | $73,137 | 144 | Eli Lilly and Company ($51,280) |
| 2019 | $87,065 | 113 | EMD Serono, Inc. ($33,870) |
| 2018 | $129,398 | 93 | EMD Serono, Inc. ($39,662) |
| 2017 | $133,196 | 131 | EMD Serono Research & Development Institute ($38,484) |
All Payment Transactions
505 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/28/2024 | BioNTech SE | — | Consulting Fee | Cash or cash equivalent | $6,162.50 | General |
| 10/15/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $997.50 | General |
| 10/11/2024 | BioNTech SE | — | Travel and Lodging | In-kind items and services | $8,922.42 | General |
| 10/11/2024 | BioNTech SE | — | Travel and Lodging | In-kind items and services | $504.45 | General |
| 10/11/2024 | BioNTech SE | — | Travel and Lodging | In-kind items and services | $245.70 | General |
| 10/11/2024 | BioNTech SE | — | Food and Beverage | In-kind items and services | $81.89 | General |
| 10/11/2024 | BioNTech SE | — | Food and Beverage | In-kind items and services | $72.70 | General |
| 10/11/2024 | BioNTech SE | — | Food and Beverage | In-kind items and services | $48.04 | General |
| 10/11/2024 | BioNTech SE | — | Food and Beverage | In-kind items and services | $25.11 | General |
| 10/11/2024 | BioNTech SE | — | Food and Beverage | In-kind items and services | $25.11 | General |
| 09/17/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,268.75 | General |
| 09/15/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $665.00 | General |
| 09/15/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $134.38 | General |
| 09/11/2024 | ABBVIE INC. | — | — | Cash or cash equivalent | $1,450.00 | Research |
| Study: A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | ||||||
| 08/30/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Consulting Fee | In-kind items and services | $5,600.00 | General |
| Category: Oncology | ||||||
| 08/17/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Travel and Lodging | In-kind items and services | $66.00 | General |
| Category: Oncology | ||||||
| 08/17/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $65.07 | General |
| Category: Oncology | ||||||
| 08/17/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $50.79 | General |
| Category: Oncology | ||||||
| 08/16/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Travel and Lodging | In-kind items and services | $194.26 | General |
| Category: Oncology | ||||||
| 08/16/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Travel and Lodging | In-kind items and services | $86.70 | General |
| Category: Oncology | ||||||
| 08/16/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $77.23 | General |
| Category: Oncology | ||||||
| 06/03/2024 | BioNTech SE | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 09/09/2023 | BioNTech SE | — | Food and Beverage | In-kind items and services | $44.84 | General |
| 03/02/2021 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $198.96 | General |
| 06/16/2020 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $5,200.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| M16-298 | AbbVie, Inc. | $2,800 | 2 |
| A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | ABBVIE INC. | $1,450 | 1 |
| A PHASE 3, RANDOMIZED, BLINDED, PLACEBO-CONTROLLED STUDY OF TISLELIZUMAB (BGB-A317) PLUS CHEMORADIOTHERAPY FOLLOWED BY TISLELIZUMAB MONOTHERAPY IN NEWLY DIAGNOSED, STAGE III SUBJECTS WITH LOCALLY ADVANCED, UNRESECTABLE NON-SMALL CELL LUNG CANCER (BGB-A317-NSCL-001) | Celgene Corporation | $1,428 | 1 |
| ATEZOLIZUMAB VERSUS PLACEBO AS ADJUVANT THERAPY IN LOCALLY ADVANCED HEAD AND NECK CANCER | Genentech, Inc. | $1,320 | 1 |
| M16-289 | AbbVie, Inc. | $550.00 | 1 |
| MS200647-0005 | EMD Serono, Inc. | $482.29 | 7 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 63 | 94 | $37,618 | $7,829 |
| 2022 | 3 | 59 | 95 | $33,704 | $7,319 |
| 2021 | 5 | 110 | 238 | $78,379 | $24,172 |
| 2020 | 6 | 144 | 255 | $95,582 | $25,624 |
Total Patients
376
Total Services
682
Medicare Billing
$64,945
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 34 | 56 | $19,704 | $4,466 | 22.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 16 | 20 | $13,524 | $2,383 | 17.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 13 | 18 | $4,390 | $979.70 | 22.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 30 | 54 | $18,198 | $4,149 | 22.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 11 | 17 | $9,943 | $2,072 | 20.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 18 | 24 | $5,563 | $1,099 | 19.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 54 | 107 | $35,161 | $8,724 | 24.8% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2021 | 11 | 46 | $7,636 | $7,379 | 96.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 15 | 47 | $18,518 | $4,182 | 22.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 17 | 24 | $13,968 | $3,065 | 21.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 13 | 14 | $3,096 | $823.20 | 26.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 58 | 108 | $34,279 | $7,032 | 20.5% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2020 | 13 | 44 | $7,304 | $6,994 | 95.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 20 | 41 | $15,179 | $3,427 | 22.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 15 | 16 | $11,600 | $2,788 | 24.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 20 | 28 | $14,710 | $2,694 | 18.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 18 | 18 | $12,510 | $2,689 | 21.5% |
About Everett Vokes
Everett Vokes is a Hematology & Oncology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1932262458.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Everett Vokes has received a total of $449,910 in payments from pharmaceutical and medical device companies, with $26,869 received in 2024. These payments were reported across 505 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($328,289).
As a Medicare-enrolled provider, Vokes has provided services to 376 Medicare beneficiaries, totaling 682 services with total Medicare billing of $64,945. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Chicago, IL
- Active Since 12/18/2006
- Last Updated 10/24/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1932262458
Products in Payments
- IMFINZI (Drug) $63,282
- Tislelizumab (Drug) $11,619
- MEKINIST (Drug) $9,443
- CYRAMZA (Drug) $9,130
- TABRECTA (Drug) $8,701
- TAGRISSO (Drug) $6,333
- Tivdak (Drug) $6,140
- LIBTAYO CEMIPLIMAB-RWLC INJECTION (Biological) $3,680
- TECENTRIQ (Biological) $2,376
- Aranesp (Biological) $1,750
- OPDIVO (Biological) $1,725
- IMLYGIC (Biological) $1,575
- Abraxane (Drug) $1,200
- MSB0011359C (Biological) $482.29
- KEYTRUDA (Biological) $464.79
- Motolimod (Drug) $155.05
- Non-Covered Product (Drug) $21.43
- INC280 (Drug) $12.90
- Erbitux (Drug) $9.40
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Chicago
Michael Bishop
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Young Kwang Chae, Md, Mph, Mba, MD, MPH, MBA
Hematology & Oncology — Payments: $682,642
Hematology & Oncology $682,642
Irfan Mirza, Md, MD
Hematology & Oncology — Payments: $644,273
Hematology & Oncology $644,273
Peter Riedell
Hematology & Oncology — Payments: $374,919
Hematology & Oncology $374,919
Rita Nanda
Hematology & Oncology — Payments: $374,678
Hematology & Oncology $374,678
Randy Sweis
Hematology & Oncology — Payments: $346,946
Hematology & Oncology $346,946